Figure 5.

Daily GBZ 4.5 mg/kg reduces Bergmann glia mislocalization in 2b4 ^he 2b5 ^ho mice. WT (open symbols) and 2b4 ^he 2b5 ^ho (VWM) mice (closed symbols) were injected daily with placebo, 4.5 mg/kg S1 (S1 D4.5), 4.5 mg/kg GBZ (GBZ D4.5) or weekly with 10 mg/kg GBZ (GBZ W10). Sagittally cut brain sections were subjected to immunostaining for S100β (green) and nuclear staining with DAPI (blue). Bergmann glia are double positive for S100β and nuclear DAPI staining. Numbers of mice are n = 2 for WT placebo, WT S1 D4.5, and WT GBZ D4.5, n = 1 for WT GBZ W10, n = 5 for VWM placebo, n = 3 for VWM S1 D4.5 and VWM GBZ D4.5 and n = 4 for VWM GBZ W10. Per mouse 3–6 images were taken. Images show illustrative examples of Bergmann glia localized in the Purkinje layer in WT mice and in the Purkinje and molecular layers in 2b4 ^he 2b5 ^ho mice. Bergmann glia were counted in the Purkinje layer (normal location) and in the molecular layer (mislocalized) by a blinded researcher. Percentages of mislocalized Bergmann glia were determined by dividing the number of mislocalized by the total number of Bergmann glia (100%). Graph shows individual and mean percentages of mislocalized Bergmann glia ± SD. The percentage of mislocalized Bergmann glia in placebo‐treated 2b4 ^he 2b5 ^ho mice is significantly higher than in WT controls (p < 0.001; nested t‐test; not indicated). Treatment effects on Bergmann glia mislocalization were assessed with a nested one‐way ANOVA followed by Dunnett's correction. *p < 0.05. White bars, 15 μm. [Colour figure can be viewed at wileyonlinelibrary.com]